Sermorelin Research Peptide (RUO)

What is Sermorelin?

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the biologically active 1-29 fragment of endogenous human growth hormone-releasing hormone (GHRH), terminated as a C-terminal amide. Mechanistically it acts as a GHRH analogue: it binds the growth hormone-releasing hormone receptor (GHRHR) on somatotroph cells of the anterior pituitary, mimicking native GHRH and stimulating the synthesis and pulsatile release of endogenous growth hormone.

As a chemical compound, sermorelin (CAS 86168-78-7, molecular formula C149H246N44O42S, ~3357.93 g/mol) is typically encountered as a lyophilised powder. A branded sermorelin product was approved by the US FDA in 1997 for growth hormone deficiency but was voluntarily withdrawn from the market in 2008 for commercial reasons; there is no marketed FDA- or EMA-approved sermorelin drug today.

How Sermorelin Is Produced & Characterised

Sermorelin is a 29-mer peptide whose length, multiple Arg/Lys basic residues and C-terminal amide create opportunities for deletion sequences, oxidation at the single methionine and incomplete amidation. Industry-standard production of peptides in this class uses Fmoc solid-phase peptide synthesis (SPPS) on an amide-forming resin, with controlled coupling and capping to suppress related-substance formation. The crude peptide is typically purified on preparative dynamic axial compression (DAC) reversed-phase HPLC columns, which resolve the target sequence from closely related impurities, and is then lyophilised to a stable powder.

Analytical characterisation of such peptides generally relies on UPLC/HPLC for purity, LC-MS for confirmation of the sequence and identification of minor structural variants, and complementary assays for water content, counter-ion (e.g. acetate) content, residual solvents, methionine-oxidation level and peptide content.

Regulatory Status & Reference Context

Sermorelin is not currently an approved drug in major markets. A branded sermorelin product received US FDA approval in 1997 for growth hormone deficiency but was voluntarily withdrawn from the US market in 2008 for commercial reasons, and there is no marketed FDA- or EMA-approved sermorelin drug today.

Where sermorelin is referenced in research, characterisation documentation such as CTD Module 3 CMC sections, analytical validation data to ICH Q2(R1), impurity and structural characterisation data, and stability data are the types of records typically associated with development-stage peptides. No therapeutic or efficacy claims are made for the molecule.

Research supply from Winhycare Pharma

Winhycare Pharma supplies research-grade Sermorelin to research organisations and individual researchers for research and development purposes. Material is supplied at high purity (>99%) under stringent quality control with QC documentation, in secure packaging through global standard logistics, with dedicated technical assistance from our team. We focus on consistent quality and purity, reliable and timely supply, confidential and professional service, and long-term partnerships.

Research use only. Not for human or veterinary use, and not for use in food, drugs, medical devices or cosmetics.

To enquire, tell us the quantity you need, the purity grade, the documentation you require and the destination country. The buyer is responsible for complying with the import and use regulations that apply to Sermorelin in their country.